{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:16:37Z","timestamp":1774869397035,"version":"3.50.1"},"reference-count":48,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1254\/jphs.12003fp","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T03:13:04Z","timestamp":1334718784000},"page":"10-19","source":"Crossref","is-referenced-by-count":19,"title":["Effect of Selective Serotonin Reuptake Inhibitors via 5-HT<SUB>1A<\/SUB> Receptors on L-DOPA-Induced Rotational Behavior in a Hemiparkinsonian Rat Model"],"prefix":"10.1254","volume":"119","author":[{"given":"Masatoshi","family":"Inden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Tooyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Ng KY, Colburn RW, Kopin IJ. L-DOPA-induced release of cerebral monoamines. Science. 1970;170:76–77.","DOI":"10.1126\/science.170.3953.76"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hollister AS, Breese GR, Mueller RA. Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther. 1979;208:37–43.","DOI":"10.1016\/S0022-3565(25)31520-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 1994;667:295–299.","DOI":"10.1016\/0006-8993(94)91511-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005;1046:230–233.","DOI":"10.1016\/j.brainres.2005.04.019"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Carta M, Carlsson T, KiriK D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819–1833.","DOI":"10.1093\/brain\/awm082"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain. 2008;131:3380–3394.","DOI":"10.1093\/brain\/awn235"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease. J Neurosci. 2007;27:8011–8022.","DOI":"10.1523\/JNEUROSCI.2079-07.2007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–245.","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Vajda FJ, Solinas C. Current approaches to management of depression in Parkinson’s disease. J Clin Neurosci. 2005;12:739–743.","DOI":"10.1016\/j.jocn.2005.03.008"},{"key":"10","unstructured":"10 Weintraub D, Comella CL, Horn S. Parkinson’s disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008;14 (2 Suppl):S59–S69."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol. 2002;26:142–145.","DOI":"10.1046\/j.1365-2125.2001.01491.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Arbouw M, Moving K, Neef C, Guchelaar HJ, Egberts T. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol. 2007;63:181–187.","DOI":"10.1007\/s00228-006-0233-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970;24:485–493.","DOI":"10.1016\/0006-8993(70)90187-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Deumens R, Blokland A, Prickaerts J. Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002;175:303–317.","DOI":"10.1006\/exnr.2002.7891"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Shimohama S, Sawada H, Kitamura Y, Taniguchi T. Disease model: Parkinson’s disease. Trends Mol Med. 2003;9:360–365.","DOI":"10.1016\/S1471-4914(03)00117-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 van Kampen JM, Stoess AJ. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience. 2003;116:307–314.","DOI":"10.1016\/S0306-4522(02)00548-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Thomas H, Huganir RL. MAPK cascade signaling and synaptic plasticity. Nat Rev Neurosci. 2004;5:173–183.","DOI":"10.1038\/nrn1346"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Pavon N, Martin AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 2006;59:64–74.","DOI":"10.1016\/j.biopsych.2005.05.044"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of c AMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27:6995–7005.","DOI":"10.1523\/JNEUROSCI.0852-07.2007"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Santini E, Alcacer C, Cacciatore S, Heiman M, Hervé D, Greengard P, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009;108:621–633.","DOI":"10.1111\/j.1471-4159.2008.05831.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001;12:1123–1126.","DOI":"10.1097\/00001756-200105080-00015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Inden M, Taira T, Kitamura Y, Yanagida T, Tsuchiya T, Takata K, et al. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson’s disease rat model. Neurobiol Dis. 2006;24:144–158.","DOI":"10.1016\/j.nbd.2006.06.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Soloaga A, Thomson S, Wiggin GR, Rampersaund N, Dyson MH, Hazzakin CA, et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003;22:2788–2797.","DOI":"10.1093\/emboj\/cdg273"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol. 1980;8:558–563.","DOI":"10.1002\/ana.410080603"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther. 1981;217:189–197.","DOI":"10.1016\/S0022-3565(25)32511-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Tanaka H, Kannari K, Maeda T, Tomiyama M, Sudo T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999;10:631–634.","DOI":"10.1097\/00001756-199902250-00034"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Parent M, Wallman MJ, Gagnon D, Parent A. Serotonin innervation of basal ganglia in monkeys and humans. J Chem Neuroanat. 2011;41:256–265.","DOI":"10.1016\/j.jchemneu.2011.04.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Wallman MJ, Gagnon D, Parent M. Serotonin innervation of human basal ganglia. Eur J Neurosci. 2011;33:1519–1532.","DOI":"10.1111\/j.1460-9568.2011.07621.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296–320.","DOI":"10.1016\/j.pharmthera.2006.08.004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson’s disease. Prog Neurobiol. 2011;95:163–212.","DOI":"10.1016\/j.pneurobio.2011.08.004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci. 1993;14:262.","DOI":"10.1016\/0165-6147(93)90125-4"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 6-hydroxytryptamine release in rat hippocampus in vivo<\/I> as determined by brain microdialysis. Br J Pharmacol. 1989;96:283–290","DOI":"10.1111\/j.1476-5381.1989.tb11815.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Casanovas JM, Lesourd M, Artigas F. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br J Pharmacol. 1997;122:733–741.","DOI":"10.1038\/sj.bjp.0701420"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Kreitzer AC. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci. 2009;32:127–147.","DOI":"10.1146\/annurev.neuro.051508.135422"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry. 2009;66:603–613.","DOI":"10.1016\/j.biopsych.2009.04.025"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res. 2004;152:297–306.","DOI":"10.1016\/j.bbr.2003.10.009"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Monville C, Torres EM, Dunnett SB. Validation of the L-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull. 2005;68:16–23.","DOI":"10.1016\/j.brainresbull.2004.10.011"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Taylor JL, Bishop C, Walker PD. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav. 2005;81:887–893.","DOI":"10.1016\/j.pbb.2005.06.013"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERM1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007;62:800–810.","DOI":"10.1016\/j.biopsych.2006.11.032"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, et al. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse. 2008;62:524–533.","DOI":"10.1002\/syn.20527"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naïve MPTP monkeys. Brain Res. 1996;719:129–137.","DOI":"10.1016\/0006-8993(96)00157-6"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, et al. Chronic D1 and D2 dopaminomimetic of MPTP-denervated monkeys: effects on basal ganglia GABA(A)\/benzodiazepine receptor complex and GABA content. Neurochem Int. 1999;35:81–91.","DOI":"10.1016\/S0197-0186(99)00064-9"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouilland C, et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson’s disease. Arch Neurol. 2001;58:249–254.","DOI":"10.1001\/archneur.58.2.249"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8:355–367.","DOI":"10.1038\/nrn2132"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Deng H, Bao X, Cai W, Blacketer MJ, Belmont AS, Girton J, et al. Ectopic histone H3S10 phosphorylation causes chromatin structure remodeling in Drosophila. Development. 2008;135:699–705.","DOI":"10.1242\/dev.015362"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modification. Cell. 2000;103:263–271.","DOI":"10.1016\/S0092-8674(00)00118-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Brami-Cherrier K, Roze E, Girault JA, Betuing S, Caboche J. Role of the ERK\/MSK1 signaling pathway in chromatin remodeling and brain responses to drugs of abuse. J Neurochem. 2009;108:1323–1335.","DOI":"10.1111\/j.1471-4159.2009.05879.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Santini E, Valjent E, Fisone G. Parkinson’s disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 2008;275:1392–1399.","DOI":"10.1111\/j.1742-4658.2008.06296.x"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:26:47Z","timestamp":1742945207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/119\/1\/119_12003FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.12003fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}